betamethasone-valerate
Conditions | Yield |
---|---|
In methanol |
Conditions | Yield |
---|---|
With toluene-4-sulfonic acid In N,N-dimethyl-formamide; benzene for 1.25h; Ambient temperature; |
9α-fluoro-11β,17α,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17-valerate 21-acetate
betamethasone-valerate
Conditions | Yield |
---|---|
In methanol |
Conditions | Yield |
---|---|
With toluene-4-sulfonic acid In benzene for 4h; Heating; | 83% |
Conditions | Yield |
---|---|
With toluene-4-sulfonic acid In benzene for 4h; Heating; | 72% |
Conditions | Yield |
---|---|
Stage #1: succinic acid With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 0.5h; Inert atmosphere; Stage #2: betamethasone-valerate In dichloromethane at 20℃; Inert atmosphere; | 53% |
betamethasone-valerate
methanesulfonyl chloride
Pentanoic acid (8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11-hydroxy-17-(2-methanesulfonyloxy-acetyl)-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl ester
Conditions | Yield |
---|---|
In pyridine at 0 - 5℃; for 1.5h; |
betamethasone-valerate
(17R)-5'-butyl-4'-ethylthio-9α-fluoro-11β-hydroxy-16β-methyl-spiro-3,3'-dione
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1: pyridine / 1.5 h / 0 - 5 °C 2: 78 percent / acetone / 7 h / Ambient temperature View Scheme |
betamethasone-valerate
9α-fluoro-11β-hydroxy-16β-methyl-21-methylthio-17α-valeryloxy-1,4-pregnadiene-3,20-dione
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1: pyridine / 1.5 h / 0 - 5 °C 2: 91 percent / acetone / 1 h / Ambient temperature View Scheme |
betamethasone-valerate
21-ethylthio-9α-fluoro-11β-hydroxy-16β-methyl-17α-valeryloxy-1,4-pregnadiene-3,20-dione
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1: pyridine / 1.5 h / 0 - 5 °C 2: 53 percent / NaOMe / acetone / 0.83 h / Ambient temperature View Scheme |
betamethasone-valerate
(17R)-5'-butyl-9α-fluoro-11β-hydroxy-16β-methyl-4'-propylthio-spiro-3,3'-dione
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1: pyridine / 1.5 h / 0 - 5 °C 2: 74 percent / acetone / 7 h / Ambient temperature View Scheme |
betamethasone-valerate
9α-fluoro-11β-hydroxy-16β-methyl-21-propylthio-17α-valeryloxy-1,4-pregnadiene-3,20-dione
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1: pyridine / 1.5 h / 0 - 5 °C 2: 80 percent / NaOMe / acetone / 0.83 h / Ambient temperature View Scheme |
betamethasone-valerate
(17R)-5'-butyl-4'-butylthio-9α-fluoro-11β-hydroxy-16β-methyl-spiro-3,3'-dione
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1: pyridine / 1.5 h / 0 - 5 °C 2: 78 percent / acetone / 7 h / Ambient temperature View Scheme |
betamethasone-valerate
21-butylthio-9α-fluoro-11β-hydroxy-16β-methyl-17α-valeryloxy-1,4-pregnadiene-3,20-dione
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1: pyridine / 1.5 h / 0 - 5 °C 2: 66 percent / NaOMe / acetone / 0.83 h / Ambient temperature View Scheme |
betamethasone-valerate
9α-fluoro-11β-hydroxy-16β-methyl-21-phenylthio-17α-valeryloxy-1,4-pregnadiene-3,20-dione
Conditions | Yield |
---|---|
Multi-step reaction with 2 steps 1: pyridine / 1.5 h / 0 - 5 °C 2: 45 percent / NaOMe / acetone / 0.83 h / Ambient temperature View Scheme |
betamethasone-valerate
A
(2S)-2-((1,1-Dimethylethoxycarbonyl)-amino)-3-methyl-butyric acid [11β,21-dihydroxy-3,20-dioxo-9-fluoro-16β-methyl-17-valeroyloxy -pregna-1,4-dien-21-yl] ester (Boc-Val-O-BMV)(2S)-2-((1,1-Dimethylethoxycarbonyl)-amino)-3-methyl-butyric acid [11β,21-dihydroxy-3,20-dioxo-9-fluoro-16β-methyl-17-valeroyloxy -pregna-1,4-dien-21-yl] ester (Boc-Val-O-BMV)
Conditions | Yield |
---|---|
With dmap In 1,4-dioxane; hexane; dichloromethane | A 10.1 g (73%) B n/a |
succinic acid
(S)-2-[{({9H-fluoren-9-yl}methoxy)carbonyl}amino]pentanedioic acid
betamethasone-valerate
N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-methionine
Fmoc-L-Gln(Trt)-OH
Conditions | Yield |
---|---|
Stage #1: Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine With benzotriazol-1-ol; diisopropyl-carbodiimide In N,N-dimethyl-formamide at 25 - 32℃; for 5h; Stage #2: With piperidine In N,N-dimethyl-formamide for 0.25h; Stage #3: succinic acid; (S)-2-[{({9H-fluoren-9-yl}methoxy)carbonyl}amino]pentanedioic acid; betamethasone-valerate; N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-methionine; Fmoc-L-Gln(Trt)-OH; Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine Further stages; |
IUPAC Name: [(8S,9R,10S,11S,13S,14S,16S,17R)-9-Fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] pentanoate
Molecular Weight: 476.577483 [g/mol]
Molecular Formula: C27H37FO6
XLogP3: 3.6
H-Bond Donor: 2
H-Bond Acceptor: 7
EINECS: 218-439-3
storage temp.: 2-8 °C
Index of Refraction: 1.56
Molar Refractivity: 123.71 cm3
Molar Volume: 382.3 cm3
Surface Tension: 50.8 dyne/cm
Density: 1.24 g/cm3
Flash Point: 316 °C
Enthalpy of Vaporization: 102.31 kJ/mol
Boiling Point: 598.9 °C at 760 mmHg
Vapour Pressure: 7.72E-17 mmHg at 25 °C
Water Solubility: 9.29 mg/L at 25 °C
Melting Point: 183-184 °C
Classification Code of Betamethasone 17-valerate (CAS NO.2152-44-5): Adrenal Cortex Hormones; Anti-Inflammatory Agents; Drug / Therapeutic Agent; Glucocorticoid; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Reproductive Effect
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
mouse | LD50 | intraperitoneal | 632mg/kg (632mg/kg) | Shikoku Igaku Zasshi. Shikoku Medical Journal. Vol. 29, Pg. 153, 1973. | |
mouse | LD50 | oral | 4067mg/kg (4067mg/kg) | Shikoku Igaku Zasshi. Shikoku Medical Journal. Vol. 29, Pg. 153, 1973. | |
mouse | LD50 | subcutaneous | 496mg/kg (496mg/kg) | Shikoku Igaku Zasshi. Shikoku Medical Journal. Vol. 29, Pg. 153, 1973. | |
rabbit | LD50 | subcutaneous | 61200ug/kg (61.2mg/kg) | SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Oyo Yakuri. Pharmacometrics. Vol. 28, Pg. 687, 1984. |
rat | LD50 | intraperitoneal | > 4500mg/kg (4500mg/kg) | SKIN AND APPENDAGES (SKIN): HAIR: OTHER | Oyo Yakuri. Pharmacometrics. Vol. 28, Pg. 687, 1984. |
rat | LD50 | oral | > 3gm/kg (3000mg/kg) | SKIN AND APPENDAGES (SKIN): HAIR: OTHER | Oyo Yakuri. Pharmacometrics. Vol. 28, Pg. 687, 1984. |
rat | LDLo | subcutaneous | 2gm/kg (2000mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 27, Pg. 2102, 1977. |
Poison by subcutaneous route. Moderately toxic by intraperitoneal route. Mildly toxic by ingestion. An experimental teratogen. Experimental reproductive effects. When heated to decomposition it emits toxic fumes of F−.
Hazard Codes: Xn
Risk Statements: 48
R48:Danger of serious damage to health by prolonged exposure.
Safety Statements: 22-24/25
S24/25:Avoid contact with skin and eyes.
S22:Do not breathe dust.
RIDADR: UN 2811 6.1/PG 3
WGK Germany: 2
RTECS: TU3835000
Betamethasone 17-valerate (CAS NO.2152-44-5), its Synonyms are Betamethasone valerate ; 9-Fluoro-11-beta,17,21-trihydroxy-16-beta-methylpregna-1,4-diene-3,20-dione-17-valerate ; 9-Fluoro-11beta,17,21-trihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-valerate ; Betaderm ; Betamethason-17-valerate ; Betatrex ; Betnovate ; Betnovateat ; Celestoderm ; Dermabet ; Luxiq ; Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16-methyl-17-((1-oxopentyl)oxy)-, (11beta,16beta)- ; Valisone ; Valnac ; beta-Methasone 17-valerate ; beta-Val .
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View